<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00573040</url>
  </required_header>
  <id_info>
    <org_study_id>BRONC MLD</org_study_id>
    <nct_id>NCT00573040</nct_id>
  </id_info>
  <brief_title>Radiotherapy for NSCLC to a Individualized MLD</brief_title>
  <acronym>BRONC MLD</acronym>
  <official_title>Radiotherapy for Stage I-III Non-small Cell Lung Cancer to an Individualized MLD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht Radiation Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht Radiation Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our group has shown in a modeling study that increasing the radiation dose to pre-specified
      normal tissue dose constrains could lead to increased TCP with the same NTCP. In a subsequent
      phase I trial, the investigators showed the safety of this approach. Here, the investigators
      want to investigate its efficacy in a prospective study in patients with stage I-III NSCLC,
      who are selected for radical radiotherapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients (see below) will receive radiotherapy to the primary tumor and the
      initially involved mediastinal lymph nodes to the following MLD (Mean Lung Dose):

        -  MLD=19 Gy when Fev1 and DLCO &gt; 50% of the predicted value

        -  MLD=15 Gy when Fev1 and/or DLCO 40-49% of the predicted value

        -  MLD=10 Gy when Fev1 and/or DLCO &lt;40% of the predicted value

      Other dose-constrains: spinal cord max: 54 Gy, brachial plexus (Dmax):66 Gy Minimum tumor
      dose:79.2 Gy.

      Radiotherapy will be delivered in twice-daily fractions of 1.8 Gy with 8 to 10 h as
      interfraction-interval, 5 days per week.

      The radiation doses will be specified according to ICRU 50. Lung density corrections will be
      applied, as well as all standard QA procedures. Technical requirements are the same as in
      standard practice at MAASTRO clinic.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>death</measure>
    <time_frame>2,3 and 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>-progression-free interval -Dyspnea (CTCAE 3.0) -Dysphagia (CTCAE 3.0) -Patterns of recurrence</measure>
    <time_frame>2,3 and 5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Inclusion criteria
Histological or cytological proven NSCLC
UICC stage I-III
Performance status 0-2
FeV1 and DLCO at least 30% of age-predicted value
Exclusion criteria:
Not NSCLC or mixed NSCLC and other histologies (e.g. small cell carcinoma)
Stage IV
Performance status 3 or more
FeV 1 or DLCO &lt; 30% of the age-predicted value</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        -  Histological or cytological proven NSCLC

          -  UICC stage I-III

          -  Performance status 0-2

          -  FeV 1 and DLCO at least 30% of the age-predicted value
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytological proven NSCLC

          -  UICC stage I-III

          -  Performance status 0-2

          -  FeV 1 and DLCO at least 30% of the age-predicted value

        Exclusion Criteria:

          -  Not NSCLC or mixed NSCLC and other histologies (e.g. small cell carcinoma)

          -  UICC stage IV

          -  Performance status 3 or more

          -  FeV 1 and DLCO &lt; 30% of the age-predicted value
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk De Ruysscher, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MAASTRO clinic, Maastricht Radiation Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MAASTRO clinic, Maastricht Radiation Oncology</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2007</study_first_submitted>
  <study_first_submitted_qc>December 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2007</study_first_posted>
  <last_update_submitted>July 20, 2010</last_update_submitted>
  <last_update_submitted_qc>July 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2010</last_update_posted>
  <responsible_party>
    <name_title>MAASTRO clinic</name_title>
    <organization>MAASTRO clinic</organization>
  </responsible_party>
  <keyword>Radiotherapy</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Stage III non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

